AAO: Corneal Toxicity Reported With Mirvetuximab Soravtansine
Corneal toxicity not uncommon with MIRV treatment for primary gynecologic malignancies, usually resolves
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.